NCT04921358 2025-06-29
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
BeiGene
Phase 3 Terminated
BeiGene
University of Birmingham
Yale University
Mirati Therapeutics Inc.
Fudan University
Mirati Therapeutics Inc.